{"id":17241,"date":"2020-05-15T15:02:00","date_gmt":"2020-05-15T13:02:00","guid":{"rendered":"https:\/\/www.hollandbio.nl\/?p=17241"},"modified":"2020-05-19T15:07:18","modified_gmt":"2020-05-19T13:07:18","slug":"lava-therapeutics-and-janssen-to-develop-bi-specific-gamma-delta-t-cell-engager-therapeutics","status":"publish","type":"post","link":"https:\/\/www.hollandbio.nl\/en\/nieuws\/lava-therapeutics-and-janssen-to-develop-bi-specific-gamma-delta-t-cell-engager-therapeutics\/","title":{"rendered":"Lava Therapeutics and Janssen to develop Bi-specific Gamma-Delta T-cell Engager Therapeutics"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Lava Therapeutics has entered into a research and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, to discover and develop novel bispecific antibodies to gamma-delta T cells for the treatment of cancer. The collaboration was facilitated by Johnson &amp; Johnson Innovation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cWe are excited to enter into this collaboration with Janssen, a global innovator and leader in the development of new medicines,\u201d said Stephen Hurly, chief executive officer of Lava Therapeutics. \u201cWe strongly believe in the strength of our bispecific gamma-delta T cell engager platform and are committed to creating highly potent, target-specific therapeutics with increased durability and safety over current T cell-based approaches.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Under the terms of the agreement, Lava Therapeutics will perform discovery and product development activities, and is eligible to receive an undisclosed financial package consisting of an upfront payment and potential development and commercial milestones, and future tiered royalties.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Source: <a href=\"https:\/\/lavatherapeutics.com\/news\/research-and-license-agreement-with-janssen-biotech\/\"><strong>Lava Therapeutics (press release)<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lava Therapeutics has entered into a research and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, to discover and develop novel bispecific antibodies to gamma-delta T cells for the treatment of cancer. The collaboration was facilitated by Johnson &amp; Johnson Innovation. \u201cWe are excited to enter into [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[39,43],"tags":[],"class_list":["post-17241","post","type-post","status-publish","format-standard","hentry","category-gezondheid","category-innovatieklimaat"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lava Therapeutics and Janssen to develop Bi-specific Gamma-Delta T-cell Engager Therapeutics - hollandbio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/lava-therapeutics-and-janssen-to-develop-bi-specific-gamma-delta-t-cell-engager-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lava Therapeutics and Janssen to develop Bi-specific Gamma-Delta T-cell Engager Therapeutics - hollandbio\" \/>\n<meta property=\"og:description\" content=\"Lava Therapeutics has entered into a research and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, to discover and develop novel bispecific antibodies to gamma-delta T cells for the treatment of cancer. The collaboration was facilitated by Johnson &amp; Johnson Innovation. \u201cWe are excited to enter into [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/lava-therapeutics-and-janssen-to-develop-bi-specific-gamma-delta-t-cell-engager-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"hollandbio\" \/>\n<meta property=\"article:published_time\" content=\"2020-05-15T13:02:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-05-19T13:07:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"hollandbio\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:site\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hollandbio\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/lava-therapeutics-and-janssen-to-develop-bi-specific-gamma-delta-t-cell-engager-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/lava-therapeutics-and-janssen-to-develop-bi-specific-gamma-delta-t-cell-engager-therapeutics\\\/\"},\"author\":{\"name\":\"hollandbio\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/833d6a25b39946e61c6101af1fa96fbb\"},\"headline\":\"Lava Therapeutics and Janssen to develop Bi-specific Gamma-Delta T-cell Engager Therapeutics\",\"datePublished\":\"2020-05-15T13:02:00+00:00\",\"dateModified\":\"2020-05-19T13:07:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/lava-therapeutics-and-janssen-to-develop-bi-specific-gamma-delta-t-cell-engager-therapeutics\\\/\"},\"wordCount\":167,\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"articleSection\":[\"Gezondheid\",\"Innovatieklimaat\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/lava-therapeutics-and-janssen-to-develop-bi-specific-gamma-delta-t-cell-engager-therapeutics\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/lava-therapeutics-and-janssen-to-develop-bi-specific-gamma-delta-t-cell-engager-therapeutics\\\/\",\"name\":\"Lava Therapeutics and Janssen to develop Bi-specific Gamma-Delta T-cell Engager Therapeutics - hollandbio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\"},\"datePublished\":\"2020-05-15T13:02:00+00:00\",\"dateModified\":\"2020-05-19T13:07:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/lava-therapeutics-and-janssen-to-develop-bi-specific-gamma-delta-t-cell-engager-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/lava-therapeutics-and-janssen-to-develop-bi-specific-gamma-delta-t-cell-engager-therapeutics\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/lava-therapeutics-and-janssen-to-develop-bi-specific-gamma-delta-t-cell-engager-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lava Therapeutics and Janssen to develop Bi-specific Gamma-Delta T-cell Engager Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"name\":\"hollandbio\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\",\"name\":\"hollandbio\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"width\":218.664,\"height\":29.659,\"caption\":\"hollandbio\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/hollandbio\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hollandbio\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/833d6a25b39946e61c6101af1fa96fbb\",\"name\":\"hollandbio\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lava Therapeutics and Janssen to develop Bi-specific Gamma-Delta T-cell Engager Therapeutics - hollandbio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hollandbio.nl\/en\/nieuws\/lava-therapeutics-and-janssen-to-develop-bi-specific-gamma-delta-t-cell-engager-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"Lava Therapeutics and Janssen to develop Bi-specific Gamma-Delta T-cell Engager Therapeutics - hollandbio","og_description":"Lava Therapeutics has entered into a research and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, to discover and develop novel bispecific antibodies to gamma-delta T cells for the treatment of cancer. The collaboration was facilitated by Johnson &amp; Johnson Innovation. \u201cWe are excited to enter into [&hellip;]","og_url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/lava-therapeutics-and-janssen-to-develop-bi-specific-gamma-delta-t-cell-engager-therapeutics\/","og_site_name":"hollandbio","article_published_time":"2020-05-15T13:02:00+00:00","article_modified_time":"2020-05-19T13:07:18+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png","type":"image\/png"}],"author":"hollandbio","twitter_card":"summary_large_image","twitter_creator":"@hollandbio","twitter_site":"@hollandbio","twitter_misc":{"Written by":"hollandbio","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/lava-therapeutics-and-janssen-to-develop-bi-specific-gamma-delta-t-cell-engager-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/lava-therapeutics-and-janssen-to-develop-bi-specific-gamma-delta-t-cell-engager-therapeutics\/"},"author":{"name":"hollandbio","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/833d6a25b39946e61c6101af1fa96fbb"},"headline":"Lava Therapeutics and Janssen to develop Bi-specific Gamma-Delta T-cell Engager Therapeutics","datePublished":"2020-05-15T13:02:00+00:00","dateModified":"2020-05-19T13:07:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/lava-therapeutics-and-janssen-to-develop-bi-specific-gamma-delta-t-cell-engager-therapeutics\/"},"wordCount":167,"publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"articleSection":["Gezondheid","Innovatieklimaat"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/lava-therapeutics-and-janssen-to-develop-bi-specific-gamma-delta-t-cell-engager-therapeutics\/","url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/lava-therapeutics-and-janssen-to-develop-bi-specific-gamma-delta-t-cell-engager-therapeutics\/","name":"Lava Therapeutics and Janssen to develop Bi-specific Gamma-Delta T-cell Engager Therapeutics - hollandbio","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/#website"},"datePublished":"2020-05-15T13:02:00+00:00","dateModified":"2020-05-19T13:07:18+00:00","breadcrumb":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/lava-therapeutics-and-janssen-to-develop-bi-specific-gamma-delta-t-cell-engager-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hollandbio.nl\/en\/nieuws\/lava-therapeutics-and-janssen-to-develop-bi-specific-gamma-delta-t-cell-engager-therapeutics\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/lava-therapeutics-and-janssen-to-develop-bi-specific-gamma-delta-t-cell-engager-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.hollandbio.nl\/en\/"},{"@type":"ListItem","position":2,"name":"Lava Therapeutics and Janssen to develop Bi-specific Gamma-Delta T-cell Engager Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.hollandbio.nl\/en\/#website","url":"https:\/\/www.hollandbio.nl\/en\/","name":"hollandbio","description":"","publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hollandbio.nl\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.hollandbio.nl\/en\/#organization","name":"hollandbio","url":"https:\/\/www.hollandbio.nl\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","contentUrl":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","width":218.664,"height":29.659,"caption":"hollandbio"},"image":{"@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/hollandbio","https:\/\/www.linkedin.com\/company\/hollandbio\/"]},{"@type":"Person","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/833d6a25b39946e61c6101af1fa96fbb","name":"hollandbio"}]}},"_links":{"self":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/17241","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/comments?post=17241"}],"version-history":[{"count":0,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/17241\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/media?parent=17241"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/categories?post=17241"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/tags?post=17241"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}